Swiss Regulators to Consider Cx601 as a Treatment for Crohn’s-related Anal Fistulas

Swiss Regulators to Consider Cx601 as a Treatment for Crohn’s-related Anal Fistulas
Swiss regulators have agreed to review Cx601 as a treatment for Crohn’s-disease-related skin sores known as complex perianal fistulas. The Swiss Agency for Therapeutic Products, or Swissmedic, granted orphan drug status to the stem cell therapy in September 2016 — recognition that better treatments are needed for the rare, debilitating condition. The European Medicine Agency’s Committee for Medicinal Products for Human

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *